abdominal diseases
Conditions
Interventions
Tegileredine group:30 minutes before the end of the surgery, intravenous injection of a loading dose of 0.5 mg (5 mL), a single dose of 0.05 mg (1 mL) from a PCA pump, and locking for 20 minutes.
Sufentanail group:30 minutes before the end of the surgery, a loading dose of 5 ug (5 mL) was intravenously injected, and a single dose of 0.5 ug (1 mL) was administered through a PCA pump, which was
Sponsors
Chengdu Jinniu District People’s hospital
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age >=65 years old, gender is not limited; 2. ASA I-III grade; 3. Patients who plan to undergo elective laparoscopic surgery under general anesthesia with intubation; 4. Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Known or suspected history of opioid intolerance; 2. Severe respiratory depression, such as oxygen saturation below 90%; 3. Having a history of chronic pain or using opioids or other pain modulators within the previous 2 weeks; 4. Acute or severe bronchial asthma; 5. Severe hepatic insufficiency; 6. Known or suspected gastrointestinal obstruction, including paralytic ileus; 7. Seizures; 8. Known or suspected history of alcoholism or drug abuse; 9. Severe cardiovascular diseases such as unstable angina pectoris and severe arrhythmia; 10. Other chronic diseases that may affect postoperative pain assessment, such as diabetic neuropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Static and dynamic VAS scores;Occurrence of adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total opioid use;Satisfaction with analgesia; | — |
Countries
China
Contacts
Public ContactGuiying Qi
Chengdu Jinniu District People’s hospital
Outcome results
None listed